The Association of Community Cancer Centers (ACCC) has joined with the Oncology Nursing Society (ONS) and The France Foundation (TFF) to support a series of live Grand Rounds/Tumor Boards on “PARP Inhibitors: Advancing Personalized Medicine for Metastatic Breast Cancer Patients.”
We are pleased to offer an exclusive opportunity to ACCC member cancer programs and practices to participate in this Grand Rounds program. All selected programs will receive a $250 stipend.
For the Grand Rounds program, a subject matter expert will travel to participating institutions to lead a one-hour accredited session that will feature a didactic presentation and an interactive Q & A session. Space is limited, apply as soon as possible to reserve the best date and time for your institution.
This dynamic program will provide the multidisciplinary cancer team with strategies to appropriately incorporate genetic testing and poly (ADP-ribose) polymerase (PARP) inhibitor therapy for patients with metastatic breast cancer (MBC). As a result of this activity, learners will be able to:
Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
Interpret the results of genomic testing accurately, including working effectively with genetic counselors
Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer
Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Explain emerging information and ongoing clinical trials associated with PARP inhibitors
Audience: This Grand Rounds program is targeted to medical oncologists, nurses, nurse practitioners, physician assistants, pharmacists, and all other healthcare professionals involved in the care and treatment of metastatic breast cancer patients in the community cancer care setting.
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit (s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation. ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.
MAINTENANCE OF CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
These educational activities are supported by an educational grant from Pfizer, Inc.